BISOPROLOL AND CHRONIC HEART FAILURE


A.A. Kirichenko

Department of Therapy SBEI FPE RMAPE, Moscow
Therapy with β-adrenergic receptor blockers leads to a decrease in the risk of death and serious cardiovascular complications in patients with chronic heart failure (CHF). Treatment with β- blockers has a particular significant effect on the risk of fatal ventricular arrhythmias in patients with high risk of sudden death. Bisoprolol is metabolically neutral and has good bioavailability, long half-life, and balanced clearance. High efficacy and good tolerability allows to consider this drug as one of the main medicines recommended for use in patients with CHF.

About the Autors


A.A. Kirichenko – Department of Therapy SBEI FPE RMAPE, Moscow


Similar Articles


Бионика Медиа